NCT05952596 - A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 17, 2023

Primary Completion Date

October 31, 2023

Study Completion Date

March 31, 2024

Conditions

DiphtheriaTetanusPertussisPoliomyelitisHepatitis BHaemophilus Influenzae Type b Infection

Interventions

BIOLOGICAL

DTaP-HepB-IPV-Hib vaccine

Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acelluar Pertussis-Hepatitis B-Sabin Inactivated Poliovirus-Haemophilus influenzae type b vaccine)

BIOLOGICAL

DTaP-HepB-IPV-Hib vaccine

Hexavalent vaccine (DTaP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-poliomyelitis(inactived)-Haemophilus influenzae type b vaccine)